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Viral epitopesTheiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease (TMEV-IDD) is a relevant
mouse model of multiple sclerosis. Infection of susceptible SJL/J mice leads to life-long CNS virus persistence
and development of a chronic T cell-mediated autoimmune demyelinating disease triggered via epitope
spreading to endogenous myelin epitopes. Potent CNS-inﬁltrating CD8+ T cell responses to TMEV epitopes
have previously been shown to be induced in both disease-susceptible SJL/J and resistant C57BL/6 mice, in
which the virus is rapidly cleared. Speciﬁc tolerization of SJL CD8+ T cells speciﬁc for the immunodominant
TMEV VP3159–166 epitope has no effect on viral load or development of clinical TMEV-IDD, but adoptive
transfer of activated CD8+ VP3159–166-speciﬁc T cell blasts shortly after TMEV infection to boost the early
anti-viral response leads to clearance of CNS virus and protection from subsequent TMEV-IDD. These studies
have important implications for vaccine strategies and treatment of chronic infections in humans.logy, Northwestern University,
312 503 1154.
iller).
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Theiler'smurine encephalomyelitis virus (TMEV) infection leads to a
chronic-progressive, paralytic demyelinating disease (TMEV-induced
demyelinating disease, TMEV-IDD) in susceptible mice that is used as a
model formultiple sclerosis (MS). The clinical progression of TMEV-IDD
is similar to the primary progressive form of MS, which occurs in about
15% of patients (Sospedra and Martin, 2005). Focal areas of demyelin-
ation and leukocyte inﬁltration are commonly found in CNS tissue from
both TMEV-IDD mice and MS patients. (Bruck, 2005; Traugott et al.,
1983). This inﬁltrate includes microglia/macrophages and clonally
expanded T cells (Lipton and Jelachich, 1997).
TMEV infection leads to TMEV-IDD only in certain strains of mice,
SJL mice being the prototypic susceptible strain. Following intracere-
bral inoculation, virus initially infects gray matter before spreading
into CNS white matter tissue (Lipton and Jelachich, 1997). TMEV
persists indeﬁnitely at varying levels in various cell types including
monocytes, microglia, oligodendrocytes, and astrocytes (Clatch et al.,
1990; Jelachich et al., 1995; Qi and Dal, 1996; Stroop et al., 1981). The
onset of clinical signs of disease occurs around day 30–35 post-
infection (p.i.) and demyelination is initiated by TMEV-speciﬁc pro-
inﬂammatory CD4+ T cells which are activated by virus epitopes
presented by CNS-resident macrophages, microglia and dendritic cells(DCs). Disease presents ﬁrst as a gait disturbance that steadily increases
in severity and progresses to incontinence and paralysis. Encephalito-
genic CD4+ T cells speciﬁc for the immunodominant epitope onmyelin
proteolipid protein (PLP139–151) arise via epitope spreading in mice
2–4 weeks after the onset of demyelination, and immune responses to
additional encephalitogenic myelin epitopes arise in an ordered fashion
as disease progresses. These myelin-speciﬁc autoreactive T cells are
activateddirectly in the inﬂamedCNS(McMahonet al.) andplayamajor
role in mediating chronic pathology of TMEV-IDD.
Other strains of mice, such as C57BL/6 (B6) mice, are resistant to
this demyelinating disease and efﬁciently clear the virus from the CNS
within 2 weeks of intracranial inoculation. Since disease resistance in
part maps to the H-2D MHC class I locus, the CD8+ T cell response to
TMEV has been extensively studied (Bureau et al., 1998; Rodriguez
and David, 1985; Rodriguez et al., 1986). In some studies, B6 mice that
are genetically deﬁcient in or have been depleted of CD8+ cells
variably develop mild signs of clinical disease (Palma et al., 2001),
though most mice become susceptible to demyelination but not
overt disease (Fiette et al., 1993; Pullen et al., 1993; Rivera-Quinones
et al., 1998; Rodriguez et al., 1993). In SJL mice, some studies have
yielded similarly contradictory results, though most tend to indicate
that a lack of CD8+ cells results in an earlier onset/more severe
disease (Begolka et al., 2001; Borrow et al., 1992; Murray et al., 1998).
The tentative association between the presence of functional CD8+
T cells and resistance to TMEV-IDD has led to direct comparison of
CD8+ T cell responses to TMEV in SJL and B6 mice. It is interesting to
note that though these responses have some qualitative differences,
they are quantitatively quite similar (Lyman et al., 2004). Thus, the
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are not clear. For both strains of mice, the CD8+ T cell response to
TMEV consists of one immunodominant epitope and two subdomi-
nant epitopes. In SJL mice, the hierarchy of immunodominance is as
follows: VP3159–166NVP3173–181NVP111–20 (Kang et al., 2002).
Chronic infections in humans, such as HIV, Hepatitis viruses, and
human Herpes viruses, pose major public health risks. Vaccines and
treatments for humans, including those designed to utilize the host's
natural CD8+T cell response against the virus, havebeen investigatedbut
have so far been largely disappointing (Letvin, 2006;Michel andMancini-
Bourgine, 2005; Riddell et al., 1996). In the current report, we used TMEV
infectionof SJLmice as amodel of chronic virus infection leading toorgan-
speciﬁc autoimmunity anddetermined that theCD8T cell response to the
immunodominant TMEVVP3159–166 epitope,which is normally unable to
clear the virus, is in fact completely dispensable during the normal
immune response to the virus. However, adoptive transfer of activated
VP3159–166-speciﬁc CD8+ T cells leads to complete clearance of CNS virus
and subsequent protection from clinical TMEV-IDD.
Results
Tolerance to the immunodominant CD8 T cell epitope does not accelerate
onset of clinical TMEV-IDD in SJL mice
Past studies from our laboratory and others have indicated that in
SJL mice lacking CD8+ cells, TMEV infection can lead to a disease of
earlier onset and/or enhanced severity (Begolka et al., 2001; BorrowFig. 1. The immunodominant response to TMEV in SJL mice is speciﬁcally inhibited by tolera
mice were injected i.v. with 200 μl of PBS containing 100 μg of VP3159–166 or sham peptide (V
lysis assays were carried out to address the capacity of CD8 T cells to lyse VP3159–166-load
responses to VP3159–166 on days 7, 17, and 30 p.i. (B). For panel (C), naive mice, mice prime
assessed for their IFN-γ responses to VP3159–166 and the subdominant VP3173–181 and VP1
assessing responses to the three SJL TMEV epitopes at day 7 p.i. in VP3159–166 tolerizedmice (D
group. Percent lysis or IFN-γ production is signiﬁcantly greater than appropriate control: *pet al., 1992; Murray et al., 1998). However, no study to date has
explored the CD8+ T cell response to this virus precisely enough to
determine the extent of the role of responses to the immunodominant
CD8+T cell epitope. Our initial goalwas to determinewhether a lack of
only the immunodominant TMEV CD8+ T cell epitope (VP3159–166) at
the timeof infectionwould lead to an enhancement of disease and viral
persistence similar to that seen in studies inwhich the entire CD8+ cell
population was absent. To approach this question, we needed to ﬁrst
establish a model by which we could speciﬁcally suppress this
response without affecting other responses or causing undesirable
side effects. To determine if the CD8+ T cell response to VP3159–166
could be prevented using the injection of soluble peptide i.v., we
treated naive SJL mice with 100 μg of VP3159–166 in PBS 7 days prior to
TMEV infection. On day 6–7 p.i., we performed in vivo lysis assays and
splenic IFN-γ ELISPOTs to determine if this procedure prevented CD8+
T cell responses. Both the lytic response to VP3159–166 (Fig. 1A) and
IFN-γ production in response to VP3159–166 (Fig. 1B) were completely
inhibited by this treatment. Since virus persists in SJLmice indeﬁnitely,
and therefore there is a constant supply of antigen available for T cell
activation, wewere also interested inwhether tolerance of the CD8+ T
cell response by this method would persist for several weeks. We
performed IFN-γ ELISPOTs and in vivo lysis assays at approximately 2
and 4 weeks p.i. in mice that had received soluble VP3159–166 or sham
peptide. While the total VP3159–166-speciﬁc CD8+ T cell response in
sham peptide-treated mice waned considerably over 4 weeks p.i., the
VP3159–166-speciﬁc responses in peptide-tolerized remained at back-
ground levels (Fig. 1A, B).nce induced by i.v. injection of soluble peptide prior to virus infection. (A, B, and D) SJL
P2121–130) 7 days prior to i.c. infection with TMEV. (A) On days 6, 16, and 29 p.i., in vivo
ed target cells. ELISPOTs were performed to determine the frequency of splenic IFN-γ
d with PBS/CFA, mice primed with VP3159–166/CFA, and mice infected with TMEV were
11–20 epitopes by splenic ELISPOT on day 7 p.i. Speciﬁcity of tolerance was tested by
). All data are representative of at least 3 separate experiments containing 3–5mice per
b0.01; **pb0.001.
Fig. 2. Abrogation of the immunodominant CTL response to TMEV in SJL mice does not
inﬂuence the initiation or progression of clinical disease or the CNS viral titer. SJL mice
were injected i.v. with 100 μg VP3159–166 or sham peptide in PBS 7 days prior to TMEV
infection. (A) Mice were monitored for disease progression as outlined in the Materials
and methods for at least 75 days. Data are representative of 4 separate experiments
containing at least 5 mice per group per experiment. At early (days 4 and 9 p.i.) and late
(day 42 p.i.) time-points, brain (B) and spinal cord tissues (C) were harvested from
3 mice per group and assessed for the presence of replicating virus by plaque assay.
Data are representative of 3 separate experiments at similar time-points. No signiﬁcant
difference between sham peptide and VP3159–166 recipient mice was observed at any
time point in terms of disease score or CNS viral titer.
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speciﬁc, we examined peptide-speciﬁc CTL responses in response to
both infection with TMEV and priming with an emulsion containing
VP3159–166 and CFA. Strong VP3159–166-speciﬁc IFN-γ ELISPOTS
responses were elicited in both groups, while only TMEV infection
elicited a signiﬁcant responses to the sub-dominant CD8+ T cell
epitopes, VP3173–181 and VP111–20 (Fig. 1C). Importantly, tolerance
induced by i.v. injection of soluble VP3159–166 was shown to be
peptide speciﬁc, as ELISPOT responses to only the cognate peptide
were suppressed in mice infected with TMEV (Fig. 1D).
Our prediction was that in SJL mice, the lack of this immunodomi-
nant virus-speciﬁc CD8+ T cell response would impair viral clearance
and accelerate or exacerbate TMEV-IDD. We monitored disease
progression in SJL mice that had received 100 μg of VP3159–166 or
sham peptide 7 days prior to TMEV infection. Surprisingly, there were
no signiﬁcant differences in the time of onset or magnitude of clinical
disease score between these two groups (Fig. 2A). Viral clearance in the
CNS was also unaltered by the lack of VP3159–166-speciﬁc cells, as mice
that received soluble VP3159–166 6 days before TMEV infection had
similar CNS viral titers as those that received sham peptide. This was
true both at early time-points p.i. during the acute phase of CD8+ T cell
activation, and at later time-points during ongoing disease (Fig. 2B, C).
Therefore, the VP3159–166-speciﬁc response elicited by TMEV infection
appeared to not play a signiﬁcant role in the control of the viral infection
in CNS tissue or in protection from TMEV-IDD.
TMEV-speciﬁc CTL responses arise earlier in TMEV-resistant C57BL/6
mice than in TMEV-susceptible SJL mice
Since a lack of the CD8+CTL response to the immunodominant T cell
epitope had no effect on the progression of clinical disease or viral
clearance, we considered the possibility that VP3159–166-speciﬁc cells
are completely devoid of viral clearing capability and unable to provide
any protection from disease. This idea was counter-intuitive, however,
considering the fact that this CD8+ T cell response is elicited quite
strongly by TMEV infection. In fact, it has been reported that the CD8+
T cell response to TMEV in SJL mice is similar in magnitude and CNS
homing capability to that in TMEV-resistant B6 mice (Kang et al., 2002;
Lyman et al., 2004). The TMEV-speciﬁc B6 response has been
documented to be a particularly strong anti-viral response and, based
on our previous studies, does inﬂuence the level of viral titer in the
B6 CNS and the speed with which the virus is cleared (Getts and
Miller, 2007). It has previously been shown that at day 5 p.i., virus-
speciﬁc CD8+ T cells are present at a higher percentage in B6 mice
than in SJL mice (Lyman et al., 2004). We thought it possible that the
TMEV-speciﬁc response occurs earlier in B6 mice than it does in SJL
mice, and that this plays an important role in the susceptibility of SJL
mice to TMEV-IDD. To test this possibility, we compared B6 and SJL
peripheral CD8+ T cell responses to TMEV infection on days 4 and 7 p.i..
We found that the B6 response to TMEV is in fact detectable at day 4 p.i.,
a time-point at which it is not yet detectable in SJL mice (Fig. 3).
These data led us to hypothesize that the SJL CD8+ T cell response
to TMEV may be potent enough to mediate viral clearance and
protection from TMEV-IDD, but may not be elicited early enough after
infection to control the viral load before it reaches a critical point
beyond which the virus cannot be cleared.
Transfer of activated VP3159–166-speciﬁc T cells protects SJL mice from
development of clinical and histologic signs of TMEV-IDD by facilitating
CNS virus clearance
To address the hypothesis that an anti-viral CD8+ T cell response
that is present earlier in infection may allow better control of TMEV
infection in SJL animals, we asked if adoptive transfer of activated
VP3159–166-speciﬁc T cell blasts could lead to virus clearance and
protection from TMEV-IDD. Since priming SJL mice with theVP3159–166/CFA emulsion elicits higher numbers of peripheral CD8+
T cell responders to VP3159–166 than can be achieved with TMEV
infection (Fig. 1C), and since tetramers are not available for the SJL
strain of mouse, we chose to prime rather than infect mice to generate
VP3159–166-speciﬁc cells. Six days after VP3159–166/CFA priming,
lymph node cells were cultured with 50 μM VP3159–166 and IL-2.
After 4 days in culture, 2×106 blasts were injected i.v. into SJL mice
that had been infected with TMEV 2 days prior. To determine what
effect the transfer of VP3159–166 blasts early in infection has on virus-
speciﬁc CD4+ and CD8+ T cell responses during the acute phase of
Fig. 3. TMEV-speciﬁc CD8+ T cell responses are elicited earlier in TMEV-resistant B6
mice compared to TMEV-susceptible SJL mice. B6 (A) and SJL (B) mice were infected i.c.
with TMEV. On days 4 and 7 p.i., mice were sacriﬁced and splenic IFN-γ ELISPOTs were
performed to determine the frequency of CTL responses to the relevant immunodo-
minant and sub-dominant B6 or SJL TMEV CD8+ T cell epitopes (A and B, respectively).
Data are representative of 3 mice per time-point in 3 separate experiments.
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nant epitope (VP3159–166) and the CD4+ immunodominant epitope
(VP270–86) were measured at days 7 and 14 p.i. Mice that received
VP3159–166 blasts at day 2 p.i. had an increased CD8+ T cell response at
both time points (Figs. 4A, B). The response to the viral CD4+ epitope
VP270–86 was reduced in VP3159–166 blast recipient mice at day 7 p.i.,
(Fig. 4A), andwas equivalent to that of mice that did not receive blasts
at day 14 p.i., (Fig. 4B).
We next sought to determine what effect the increased antiviral
CD8+ T cell response had on virus persistence and the development
and progression of TMEV-IDD. B6 mice, which clear TMEV from the
CNS approximately 2 weeks after infection (Lipton and Jelachich,
1997), were used as a reference to determine whether the addition of
VP3159–166 blasts early in infection would lead to similar clearance
rates of TMEV in SJL mice. CNS tissue taken at day 14 p.i. from TMEV-
infected B6 mice, TMEV-infected SJL mice, and TMEV-infected SJL
mice that had received VP3159–166-speciﬁc blasts at day 2 p.i. showed
that as expected, B6 mice had signiﬁcantly lower viral load compared
to SJL mice that had not received VP3159–166 blasts, as two out of three
B6 mice had cleared the virus completely from the brain and the third
mouse had a fourfold lower titer compared to the TMEV-infected SJL
group (Fig. 4C). At this time point, SJL mice that had received blasts
exhibited lower viral loads compared to mice that had not received
blasts, but no mice in this group had undetectable levels of virus.
Therefore, the transfer of VP3159–166 blasts results in an increased rate of
viral clearance, but not to the same rate as that of the resistant B6 strain.
However, transfer of VP3159–166 blasts led to essentially total clearance
of CNS virus measured at 75 days p.i., in stark contrast to control TMEV-
infected SJL mice that had not received blasts, which exhibited a
signiﬁcant amount of CNS virus at this time point (Fig. 4D).To determine whether the increase in viral clearance translated to a
protective effect against TMEV-IDD, mice were monitored for clinical
signs of disease for 75 days. Transfer of VP3159–166 blasts afforded nearly
complete protection from the development of TMEV-IDD (Fig. 4E). In
each experiment, approximately 20% of VP3159–166 blast recipients
broke through and exhibited clinical signs of TMEV-IDD; however,
disease in thesemicewas of later onset andmuch less severe compared
to control TMEV-infected animals, and was in some cases transient
(Fig. 4F). Concomitant with protection from clinical disease, responses
to the immunodominant TMEV CD4+ T cell viral epitope (VP270–86) and
the immunodominant CD4+ T cell myelin epitope (PLP139–151) were
also signiﬁcantly reduced in recipients of VP3159–166 blasts compared to
control TMEV-infectedmice on day 77 p.i., indicating that the activity of
VP3159–166 blasts early in infection resulted in the resolution of the viral
infection and therefore a decline in the virus-speciﬁc T cell response
and the prevention of spreading to the myelin-speciﬁc autoimmune
response (Fig. 4G).
Lack of CNS inﬂammation and demyelination correlated with
lowered clinical disease, as control mice had distinct demyelination
in brain and spinal cord tissue as well as considerable inﬁltration of
CD4+ T cells at day 75 p.i. (Fig. 5A, C). At this time-point, VP3159–166
blast recipients at a score of 0 did not exhibit any T cell inﬁltration
or evidence of demyelination in the brain or spinal cord (Fig. 5B, D).
Those few VP3159–166 blast recipients that did break through and
develop low disease scores had correspondingly low levels of CD4+
T cell inﬁltration and demyelination in CNS tissues (data not shown).
Since the VP3159–166 CD8+ T cell blasts were transferred into SJL
mice two days after i.c. TMEV infection, we hypothesized that these
transferred CTLs would have to enter the CNS to explain the fact that
mice that are administered VP3159–166 blasts are able to clear
persistent CNS virus when the endogenous VP3159–166 response is
not able to do so. Indeed, 2 days post i.v. transfer, CFSE-labeled
VP3159–166-speciﬁc T cell blasts were demonstrable in the spleen,
liver, and lung tissue of both TMEV-infected and mock-infected
recipients, but were present in the brains of only virus-infected, and
not mock-infected, mice (Fig. 6).
Taken together, these data indicated that the absence of the
VP3159–166-speciﬁc CD8+ T cell response does not lead to an increase
in viral titer or disease, but that the transfer of VP3159–166-speciﬁc
blasts into SJL mice at day 2 p.i. results in increased CD8+ DTH
responses, increased viral clearance, and protection from TMEV-IDD.
The fact that B6 animals have a detectable response to TMEV at least
2 days earlier than SJL mice suggested to us that the timing of the
generation and arrival in the CNS of the anti-TMEV CD8+ T cell
response may play an important role, and may help us to reconcile
these apparently contradictory results. We hypothesize that the
immunodominant CD8+ T cell response in SJL mice is capable of
contributing to viral clearance, but is not generated early enough after
infection to control the virus, and therefore disease development.
Protection from TMEV-IDD in susceptible SJL mice requires transfer of
CD8+ T cells speciﬁc for the immunodominant VP3159–166 epitope
early after infection
Of the two sub-dominant SJL TMEV CD8+ T cell epitopes, one
(VP111–20) is of extremely low strength, while the other (VP3173–181)
induces a strong IFN-γ response as measured by IFN-γ ELISPOT
(Fig. 1D) and a relatively strong lytic response as measured by in vivo
lysis (data not shown). We asked whether activated CD8+ T cells
speciﬁc for the subdominant VP3173–181 epitope could similarly
protect SJL mice from TMEV-IDD. Unlike VP3159–166-speciﬁc CD8+
T cells, transfer of 2×106 VP173–181-speciﬁc T cells provided no protec-
tion from development of clinical disease in TMEV-infected SJL mice
(Fig. 7A).
To determine whether endogenous VP3159–166-speciﬁc CTLs were
required for clearance of CNS-persisting virus, 2×106 activated
106 M.T. Getts et al. / Virology 402 (2010) 102–111VP3159–166-speciﬁc T cells were transferred into TMEV-infected SJL
mice whose endogenous response had been tolerized to the
VP3159–166 peptide 2 weeks previously. We found that VP3159–166blasts were still protective in mice without functional endogenous
VP3159–166-speciﬁc cells, but protection was not as complete as when
the endogenous population was intact, suggesting that the number of
Fig. 5. Transfer of VP3159–166-speciﬁc T cell blasts protects SJL mice from CNS
demyelination and CD4+ T cell inﬁltration. SJL mice were infected with TMEV on day 0,
then mice were injected i.v. with PBS (A, C) or 2×106 VP3159–166-speciﬁc T cell blasts
(B, D) on day 2 p.i. On day 75 p.i., 5 mice per group were sacriﬁced and brain and spinal
cord tissues were harvested and frozen in liquid nitrogen. Sections were cut from frozen
tissues and stained with a ﬂuoromyelin stain (green) and anti-CD4 (red), then
counterstained with DAPI (blue). Representative cerebellum (A, B) and lumbar spinal
cord (C, D) tissue sections are shown. The PBS-treatedmouse shownwas at a score of 3 at
the time of sacriﬁce. Both CD4+ cells and a lack of myelin staining are evident in both
cerebellum and spinal cord tissue (A, C). The VP3159–166 T cell blast recipient picturedwas
at a score of 0 and shows intact myelin and a lack of CD4+ T cell inﬁltration (B, D).
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cells, is an important factor in VP3159–166-dependent protection
(Fig. 7B). These data also show that the endogenous population of
VP3159–166-speciﬁc cells is functional, and not dispensable in this
adoptive transfer scenario, unlike under the normal circumstances of
TMEV infection in SJL mice.
Finally, we investigated when during the course of infection that
adoptively transferred VP3159–166-speciﬁc CTLs were required to
mediate protection from TMEV-IDD. VP3159–166-speciﬁc blasts were
protective when transferred at day 2 p.i., but provided no protection
when injected on day 7 p.i. (Fig. 7C), the time point at which the
endogenous TMEV-speciﬁc response reaches its peak in SJL mice. This
observation indicated that the blasts must be provided early after
infection, and prior to the peak of the naturally occurring response, to
offer any protection from the onset of TMEV-IDD.
Discussion
The CD8+ cytolytic T cell response to TMEV in SJL mice has been
shown to be relatively robust as indicated by measurements of IFN-γ
production and lytic capacity, yet the response is incapable of clearing
virus, allowing establishment of a life-long persistent infection and
resulting in the induction of a chronic CNS demyelinating disease via
epitope spreading (Ercolini and Miller, 2009; Munz et al., 2009). We
sought to deﬁne the anti-viral capacity of the CD8+ T cell response in
TMEV-susceptible SJL mice to the immunodominant VP3159–166
epitope. Surprisingly, speciﬁc inactivation of the response to theFig. 4. Transfer of VP3159–166-speciﬁc T cell blasts increases early anti-viral CD8+ T cell res
TMEV-IDD. Mice were administered 2×106 VP3159–166-speciﬁc blasts in PBS on day 2 post TM
(VP3159–166, right ear) epitopes were measured at days 7 (A) and 14 (B) p.i. Data are represe
**pb0.02. (C) Mice were sacriﬁced on day 14 p.i. and assessed for viral titer in brain tis
representative of 3mice per group. *pb0.07betweenblast recipient SJL and control SJLmice; **p
were sacriﬁced and assessed for viral titer inbrain tissuebyplaque assay. CNS viruswas essentia
as compared PBS-treated controls: *pb0.001. Clinical diseasewasmonitored bymean clinical di
p.i. Data are representative of 5 experiments of 5–10 mice per group. Blast recipient scores an
pb0.001. DTH in response to the dominant CD4myelin autoepitope PLP139–151 (left ear) or the d
presented as mean ear swelling±SD and are representative of 2 separate experiments of 5
signiﬁcantly lower in VP3159–166 blast recipients than PBS-treated controls: *p=0.01; **p=0.0immunodominant VP3 epitope in peptide tolerized mice had no effect
on disease course or viral load (Figs. 1 and 2). This result was
interesting in light of the fact that past experiments have shown
that SJL mice lacking the entire CD8+ cell population (which would
includeCD8+cells of any type includingCD8α+dendritic cells), ormore
speciﬁcally lacking functional CD8+ cytolytic T cells, are susceptible to
an earlier onset and/or more severe form of TMEV-IDD (Begolka et al.,
2001; Borrow et al., 1992; Murray et al., 1998). These results appear to
indicate that the VP3159–166-speciﬁc CD8+ T cell response does not
contribute signiﬁcantly to the protection conferred by the CD8+ T cell
response as a whole. Therefore, we reasoned that the CD8+ T cell-
mediatedprotectionevidencedbypast studiesmustbemediatedbyone
or several other CD8+ T cell populations directed against one or both of
the two known sub-dominant epitopes. However, this possibility seems
unlikelydue to theminimal natureof theVP111–20-speciﬁc response and
the fact that VP3173–181-speciﬁc blasts were not protective upon
adoptive transfer to SJL mice two days p.i. (Fig. 7). Alternatively, or
perhaps additionally, it could be the activity or lack thereof of some
other CD8+ T cell population, such as a population of regulatory cells,
that leads to enhanced disease in CD8-deﬁcient SJL mice. As precedent
for this possibility, BALB/cByJ mice, which are resistant to TMEV, have
been shown to possess a population of CD8+ T cells that mediates
protection not by enhancing viral clearance, but by directly suppressing
auto-reactive CD4+ T cell responses (Haynes et al., 2000; Nicholson
et al., 1999).Whether a similar CD8+ regulatory population exists in SJL
mice is currently not known.
It was especially surprising that speciﬁc tolerization of the
VP3159–166-speciﬁc response had no effect on TMEV titers in infected
SJL mice. It was once thought that the TMEV-speciﬁc CD8+ T cell
response in SJL mice was far inferior to that in B6 mice. However, a
direct comparison of the CD8+ T cell responses in these strains of
mice revealed that, in fact, the responses in SJL and B6 mice were
quantitatively comparable, and both are strongly activated in the
CNS (Lyman et al., 2004). Therefore, we had expected that the
absence of this virus-speciﬁc CD8+ T cell response, which is high
frequency, functionally effective in lysing virus-infected target cells,
and capable of migrating to the site of infection, would have obvious
effects on the viral load of the CNS, if not in the development of
TMEV-IDD. Our observation that the CD8+ T cell response to TMEV is
mounted earlier in resistant B6 mice as compared to susceptible
SJL mice provided a possible explanation for this discrepancy in
virus clearance and ultimate disease susceptibility between the
two strains (Fig. 3).
Surprisingly, we found that although the absence of the VP3159–166-
speciﬁc CD8+ T cell response had no effect on viral clearance or
TMEV-IDD outcome, these parameters could be drastically affected
by boosting the same CD8+ T cell response through supplying
VP3159–166-speciﬁc CD8+ T cell blasts early after infection. The
temporal aspect of the CD8+ T cell response may explain these
apparently contradictory ﬁndings. In B6 mice, the CD8+ T cell
response is elicited early after infection and is capable of eradicating
the virus before it becomes overwhelming. Our ﬁndings suggest that
the TMEV-speciﬁc CD8+ T cell response in SJL mice is less able to
clear TMEV compared to B6 mice because the response in SJL mice is
not elicited early enough to control the infection, allowing eventualponses, reduces CNS virus persistence, and protects SJL mice from the development of
EV infection. DTH responses to the dominant viral CD4+ (VP270–86, left ear) and CD8+
nted as mean ear swelling±SEM and are representative of 4 mice per group; *pb0.03,
sue by plaque assay. Data are represented as mean pfu/mg of tissue±SEM and are
b0.02between B6animals andblast recipient SJLmice. (D)Onday 75p.i., 3mice per group
lly undetectable (fewer than1 PFU/mg tissue) in the recipients ofVP3159–166-speciﬁc blasts
sease score (E) and percentage ofmice displaying clinical symptoms (F) for at least 75 days
d percent affected over the course of disease were signiﬁcantly lower than control group,
ominant TMEVCD4 epitope VP270–86 (right ear)was performed onday 75p.i. (G). Data are
mice per group. Responses to both the dominant myelin and TMEV CD4 epitopes were
02.
Fig. 6. VP3159–166-speciﬁc T cell blasts are retained in the CNS of TMEV-infected, but not mock-infected, SJL mice. VP3159–166 blasts were labeled with 2 μM CFSE prior to transfer into
SJL mice that were mock-infected or infected with TMEV 2 days previously. Two days post-transfer (day 4 p.i.), mice were sacriﬁced and spleen, liver, lung, and brain tissues were
harvested, and inﬁltrating cells analyzed by ﬂow cytometry for CFSE+ cells. For each histogram, organs from 3 mice per group were pooled. Data are representative of 3 separate
experiments.
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response may have little effect due to its inability to arrive in the
CNS in time to control viral replication, but the early boost of this
response may have a signiﬁcant effect on early control of viral
replication, resulting in better viral clearance and protection from
the development of TMEV-IDD. Studies to further test this hypoth-
esis are ongoing.
The endogenous VP3159–166-speciﬁc population appears to be
required for optimal protection. We however did not address the
possibility that the requirement for the presence of the endogenous
CTLs could be overcome by the injection of higher numbers of blasts
on day +2 p.i. It is also possible that the endogenous VP3159–166-
speciﬁc population comes into the CNS as a second wave attack on the
virus after the adoptively supplied T cell blasts have performed their
function and died.
Consistent with a crucial link between early temporal appearance
of TMEV-speciﬁc CTL activity and effective clearance of CNS-persistent
virus, we showed that peripheral adoptive transfer of 2×106 activated
VP3159–166-speciﬁc T cells on day +2, but not on day +7 p.i., resulted
in drastically reduced viral titers and highly signiﬁcant protection
from both the clinical and histopathologic signs of TMEV-IDD (Figs. 4,
5 and 7). Complete protection from TMEV-IDD occurred in 80% of
virus-infected SJL mice receiving activated VP3159–166-speciﬁc T cellblasts, andmice that did not develop signs of clinical disease were also
free of T cell inﬁltration and demyelinating lesions in the CNS. In the
remaining 20% of mice, a later onset, signiﬁcantly less severe form
of TMEV-IDD occurred, with lesser CNS inﬂammation and demyelin-
ation correlating with reduced clinical disease. Additionally SJL mice
receiving VP3159–166-speciﬁc T cell blasts cleared virus from the brain
earlier than untreated animals (Fig. 4). Early temporal appearance
of TMEV-speciﬁc CTL activity also allowed for an increase in the DTH
response to the CD8+ immunodominant epitope VP3159–166 early
after infection. Interestingly, the CD4+ T cell anti-viral response was
decreased early after infection (Fig. 4). Since the VP3159–166 CTLs
were provided on day 2 p.i., we predicted that they would likely be
recruited to and retained in the inﬂamed, virus-infected CNS. Indeed,
CFSE-labeled VP3159–166 blasts were detectable in the brain 2 days
post-transfer inmice infectedwith TMEV, but could not be detected in
brains of mock-infected mice (Fig. 5). Therefore, these cells were
retained in the CNS by the presence of the viral infection and their
presence in the site of virus persistence led to essentially total
clearance of the infection (Fig. 4).
In addition, long after the initial infection (on day 77 p.i.), SJL
recipients of VP3159–166 T cell blasts displayed signiﬁcantly lower DTH
responses to the immunodominant TMEV CD4 T cell VP270–86 epitope,
which was anticipated based on the decreased viral load at this time-
Fig. 7. CD8+ T cell blast-mediated protection from TMEV-IDD requires speciﬁcity for the
immunodominant CD8 epitope, the endogenous TMEV-speciﬁc response, and early
administration following TMEV infection. For disease courses, SJL mice were infected with
TMEV on day 0 and monitored for clinical signs of TMEV-IDD for 75 days p.i. (A) Mice were
administered 2×106 VP3159–166 or VP3173–180 blasts in PBS or PBS alone on day 2 p.i.
(B) Sevendaysprior to TMEV infection, SJLmicewere administered100 μgof solubleVP3159–
166 i.v. to deplete the endogenous VP3159–166-speciﬁc response, or PBS as a control. Two days
p.i., the two groups of mice (depleted and non-depleted) were divided into 4 equal groups
andmicewere administered either VP3159–166 blasts or PBS. (C) SJLmicewere administered
VP3159–166 blasts on either day 2 or day 7 p.i. For each graph, data are representative of 3
experiments of at least 5 mice per group. Blast recipient groups disease course signiﬁcantly
less than appropriate No Blast controls or indicated group: *pb0.05; **pb0.005.
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responses. More important to chronic CNS demyelinating pathology,
VP3159–166 T cell blast recipients had a signiﬁcantly diminished DTH
response to PLP139–151 than control mice. This endogenous myelin
peptide is the immunodominant CD4+ T cell myelin epitope in SJL
mice, and is the ﬁrst andmost important of the autoreactive responses
triggered by epitope spreading that characterize the chronic autoim-
mune phase of TMEV-IDD (McMahon et al., 2005; Miller et al., 1997;
Munz et al., 2009; Neville et al., 2002).To our knowledge, this is the initial observation that the
immunodominant CD8+ T cell response to TMEV in SJL mice is by
itself capable of protecting SJL mice from TMEV-IDD bymediating CNS
virus clearance. Collectively, our data strongly suggest that when
VP3159–166 blasts are provided to SJL mice early after i.c. infection,
these cells are able to clear the viral infection, vastly reducing the
amount of inﬂammation in the CNS. This rapid resolution of the virus
infection prevents early myelin damage and the later activation of
myelin-speciﬁc T cells via epitope spreading, reducing or preventing
autoimmune-mediated demyelination and protecting mice from the
chronic stages of clinical TMEV-IDD. Interestingly, our results indicate
that a virus-speciﬁc CD8+ T cell response that does not normally
signiﬁcantly contribute to the control of viral load or protection from
virus-induced disease can be enhanced to provide complete protec-
tion. This has interesting implications related to the use of ampliﬁed
speciﬁc CD8+ T cells in humans, as therapies against acute and chronic
viral infections aswell as tumors. Tumor-speciﬁc CD8+T cells are often
rendered tolerant within hosts (Frey and Monu, 2006). In several
studies, investigators have attempted to reverse tolerance or over-
come the immunosuppressive local environment of a tumor by
supplying tumor-speciﬁc CD8+ T cells (Dudley and Rosenberg,
2003). Studies comparing injection of CD8+ T cells at varying stages
of differentiation revealed that the less differentiated the cells, the
more protection is provided against tumors in mice (Gattinoni et al.,
2005). The cells used in our studies may correspond to the least
differentiated activated CD8+ T cells in this study, as they were
subjected to only one round of in vitro stimulation, suggesting that the
requirement for minimal differentiation extends to CD8+ T cell
responses to viral infection.
Chronic viral infections in humans, such as HIV, hepatitis viruses,
and human herpes viruses, induce CD8+ T cell responses, but these
are insufﬁcient for viral clearance (Goulder et al., 2001; McMichael,
1998; Webster and Bertoletti, 2001). In contrast to tumor studies, few
studies have been published in which antigen-speciﬁc CD8+ T cells
transfers are used for anti-viral responses, though in one study the
reactivation of CMV following bone marrow transplant could be
prevented by the administration of CMV-speciﬁc CD8+ T cell clones
isolated from the bone marrow donor (Walter et al., 1995). Many
studies have attempted to utilize other methods of amplifying host
anti-HIV CD8+ T cell responses, including the use of various methods
of targeting antigen to DCs, which in turn prime endogenous CD8+
T cells in infected hosts [reviewed in (Walsh et al., 2003)]. Our
approach, which is a more direct way of using the host's endogenous
CD8+ T cell response, may provide a new method to accomplish
adoptive immunotherapy. Immunodominant viral epitopes from an
individual could be determined and that individual's virus-speciﬁc
CD8+ T cells could be ampliﬁed ex vivo as we have described, and re-
administered to the individual to achieve effective pathogen-speciﬁc
immunotherapy. A caveat to this approach was illustrated in our system
by the necessity that the activated VP3159–166-speciﬁc T cells be
transferred early after infection to be effective against viral and auto-
immune pathogenesis. Thus, this approach may have limitations and
may not be suitable for long-established chronic infections in humans.
Regardless, our approach may be well suited to supplement vaccine
therapies, and/or anti-tumor therapies, although further researchwill be
required to conﬁrm and extend these initial observations.
Materials and methods
Mice
SJL mice were purchased from Harlan Laboratories, Bethesda, MD.
C57BL/6 mice were purchased from Jackson Laboratories, Bar Harbor,
ME. All mice were housed in the Center for Comparative Medicine,
Northwestern University, Chicago IL, under the guidelines of the
Animal Care and Use Committee (ACUC).
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All synthetic peptides were obtained from Genemed Synthesis, San
Francisco, CA. These included TMEV peptides VP2121–130 (FHAGSLLVFM),
VP2165–173 (TGYRYDSRT),VP3159–166 (FNFTAPFI),VP3173–181 (QTSYTSPTI),
VP111–20 (SNDDASVDFV), VP3110–120 (NFLFVFTGAAM), and VP270–86
(WTSQEAFSHIRIPLP), as well as PLP139–151 (HSLGKWLGHPDKF).
All peptides were puriﬁed by HPLC and were certiﬁed to be ≥95%
pure.
TMEV inoculation and evaluation of clinical disease
For all TMEV infections, strain BeAn 8386 was used. Mice were
infected by i.c. injection with 4.0–10×106 PFU of BeAn in a volume
of 30 μl serum-free Dulbecco's Modiﬁed Eagle's Medium (DMEM).
For long-term experiments, mice were monitored every 3 to 4 days
and scored for clinical disease severity. For TMEV-infected SJL mice,
the grading scale was as follows: 0, asymptomatic; 1, mild to
moderate waddling gait; 2, moderate to severe waddling gait with
extensor spasms; 3, extreme difﬁculty walking, impaired righting
reﬂex; 4, paralysis of 1 or more limbs, inability to walk; 5,
moribund. All mice were monitored daily and afforded easier
access to food and water once their symptoms became severe.
TMEV plaque assay
Mice were anesthetized with 50 mg/kg Nembutal and perfused
with 30–50 ml of PBS through the left ventricle. Spinal cords and
brains were collected from perfused mice, weighed, and homog-
enized on ice using a Polytron System PT1200C tissue homogenizer
(Kinematica AG, Switzerland). Homogenates were serially diluted
and added to tissue culture-treated plates (Nunc, Roskilde,
Denmark) of conﬂuent BHK-21 cells for a 1 h incubation at room
temperature, with periodic gentle rocking. Cells were then covered
with a media/agar solution containing 1% Noble Agar (BD, Sparks,
MD) and 2X DMEM. Following a 5 day incubation at 34 °C, formalin
(Fisher Scientiﬁc, Fair Lawn, NJ) was added and incubated at room
temperature for 1–2 h to ﬁx the BHKmonolayer. The agarwas removed
and plaques were visualized by staining with crystal violet. To
determine PFU/ml homogenate, the number of plaques on each plate
wasmultiplied by the dilution factor of the homogenate and divided by
the amount of homogenate added per plate. The PFU/mlwas divided by
the weight of the tissue to calculate PFU/mg tissue.
Soluble peptide tolerance
Micewere injected intravenously via the lateral tail veinwith 100 μg
of the indicated peptide in 200 μl PBS, 6 or 7 days prior to TMEV
infection.
In vivo cytolysis assay
Splenocytes were collected from naive animals, treated with
NH4Cl to remove red blood cells, and divided into two populations.
Each population was pulsed with either cognate or irrelevant
peptide, then the two populations were labeled with differential
concentrations of 5-carboxyﬂuorescein diacetate succinimidyl ester
(CFSE). These two populations were mixed together and injected in
equal numbers into immune (infected) or naive animals, at 6 to
10×106 total cells per mouse. After 18 to 24 h, spleens were
collected from recipients and analyzed by ﬂow cytometry on a BD
LSRII for the presence and relative numbers of cells in each CFSE
peak. Two equations were used to determine the percent lysis. The
adjustment factor (A) was calculated by dividing the percent of
cells loaded with irrelevant peptide by the percent of cells loaded
with cognate peptide in naive controls. For the percent lysisequation, the average of the A from 2 to 3 naive mice was
calculated, and the following equation was used:
Percent lysis ¼ð% irrelevant peptide × AÞ − % cognate peptide
% irrelevant peptide ×Enzyme-linked immunoSPOT (ELISPOT)
ELISPOT assays were carried out as previously described (Tompkins
et al., 2002), with the following modiﬁcations. Unless otherwise noted,
5×105 bulk splenocytes were plated per well with 0 or 50 μg of the
indicated antigen. For some experiments, CD4+ and/or CD8+ cellswere
positively or negatively selected prior to plating using Auto-Macs bead
separation (Miltenyi Biotech, Auburn, CA) according to manufacturers’
instructions. All ELISPOT data are presented as mean number of spots
per well±SD.
Adoptive transfer of CD8+ T cell blasts
Donor SJL mice were primed with an emulsion containing 1 mg/
ml peptide and incomplete Freund's adjuvant (IFA) mixed with 2 mg/
ml Mycobacterium tuberculosis H37Ra (Difco, Detroit, MI) to make
Complete Freund's adjuvant. One hundredmicroliters of emulsion per
mouse was injected subcutaneously in 3 spots on the ﬂank,
approximately 33.3 μl per spot. Seven days after priming, the axial,
brachial, and inguinal lymph nodes were collected. Single cell suspen-
sions were placed in culture with 50 μM antigen and 200 U/ml rIL-2
(Roche, Nutley, NJ) . For some experiments, splenocytes were also
collected from donormice, and depleted of CD4+ cells using Auto-Macs
bead separation (Miltenyi Biotech, Auburn, CA) prior to placing them in
culturewith antigenand rIL-2. After 4 days in culture, cellswerewashed
and blasts counted. Blasts were identiﬁed by their large size under
trypan blue examination, and 2×106 blasts in PBSwere injected i.v. per
mouse via the lateral tail vein. Among experiments, blast percentage
ranged from 12% to 26%, so the total number of cells injected varied;
however, the blast numbers remained constant.
Histology and immunohistochemistry
Brains, spinal cords, and spleens from perfused mice were
harvested and immunohistochemistry for the detection of CD4+
cells was performed as previously described (Tompkins et al., 2002).
Myelin visualization was carried out using a ﬂuoromyelin stain
(Molecular Probes, Eugene, OR), following manufacturer’s instruc-
tions. Slides were coverslipped in Vectashield mounting medium
containing DAPI (Vector Laboratories, Burlingame, CA) and analyzed
using a SPOT RT camera (Diagnostic Instruments, Sterling Heights, MI)
andMetamorph imaging software (Universal Imaging, Downingtown,
PA).
Isolation of lymphocytes from CNS, lung, and liver
Mice were anesthetized with 50 mg/kg Nembutal, then perfused
with 30–50 ml of PBS through the left ventricle. Brains, lungs, and
livers were harvested, minced with scissors and treated with Liberase
R1 (Roche, Indianapolis, IN) and DNase I (Invitrogen, Carlsbad, CA) at
37 °C with periodic gentle mixing for 45 min (for brain tissue) or 1 h
(for lung and liver tissue). Samples were pushed through 40 μmNytex
(Sefar America, Kansas City, MO) to yield a single cell suspension.
Mononuclear cells were isolated using a 30%/70% Percoll (Amersham,
Piscataway, NJ) gradient centrifuged at 2500×g for 20 min at room
temperature.
Delayed type hypersensitivity (DTH)
For each mouse, the thickness of both ears was measured using a
Mitutoyo model 7326 micrometer (Schlesinger's Tools, Brooklyn, NY)
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10 μg of peptide in 10 μl PBS, using a 100 μl Hamilton syringe and a
30 gaugeneedle. For eachmouse, PLP139–151 or VP3159–166was injected
into in one ear, VP270–86 into the other. Twenty-four hours after
injection of peptide, ear thickness was again measured. Mean ear
swelling was determined by subtracting the baseline ear width from
the second measurement.
Statistical analysis
For all in vitro and ex vivo assays, comparisons between groups were
analyzed using unpaired Student's t test. For all disease courses,
comparisons between groups were made using ANOVA. p valuesb0.05
were considered signiﬁcant.
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